Brind.

BioNTech is listed on Nasdaq and is advancing pancreatic cancer trials using Roche's Tecentriq, while also partnering with Genentech.

2 reports, 1 independent Updated Sep 7

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

BioNTech is listed on Nasdaq and is advancing pancreatic cancer trials using Roche's Tecentriq, while also partnering with Genentech.

Who's involved

What this event is mainly about

Hoffmann-La Roche Nasdaq

Keep exploring

The entities involved

Hoffmann-La Roche
Swiss healthcare company
- Dean Hakanson led U.S. Medical Affairs for the remdesivir launch and served in senior leadership positions at major pharmaceutical companies.Mon 17:32
- FDA granted 510(k) clearance for a new panel developed by Hoffmann-La Roche.Mon 16:37
Nasdaq
American fully electronic stock exchange
- Anthropic, developer of Claude Code, is seeking a listing on the Nasdaq Global Select Market.10:26
- Ascentage Pharma Group International listed its ADR on the Nasdaq exchange.10:09

Coverage

Newest first; wire copies grouped

Sep 7yahoo.com

1 more outlet ran the same wire story

Sep 7insidermonkey.com